Board

Alan Reade

• Non-Executive Chairman
• Chairman of the Nomination Committee
• Member of the Audit Committee

Mr Reade was appointed as a Non-Executive Director on May 25, 2007. In 2010 he moved to the United States to become Executive Chairman, and then in June 2013 he became Non-Executive Chairman. He is owner of Global Strategy Expression Limited, a consulting and advisory services business in the life sciences industry. From 2000 until his retirement in 2005, he served as executive chairman of Merial Limited, a leading animal health company and joint venture between Merck & Co. Inc. and Sanofi- Aventis. Earlier in his career he was head of global integration at Aventis, where he was in charge of merger integration, and Chief Executive Officer and member of the Global Management Board at Rhone-Poulenc Inc. He previously has been a director of Sygen International and IFAH, a global animal health association.

Bruno Jactel

• Chief Executive Officer
• Member of the Nomination Committee

Dr. Jactel was appointed as Chief Executive Officer (CEO) in January, 2013. He spent 12 years at Merial Limited, the US$2.6 billion revenue generating Animal Health subsidiary of the Sanofi Group, most recently as combined Chief Strategy Officer and Chief Marketing Officer. As Head of commercial operations in Europe, Dr. Jactel developed successful growth strategies in both OTC and professional channels. He was further responsible for global marketing, brand management, enterprise and franchise strategy, in addition to being a co-chair on the R&D steering committee. During this time, Merial built the most successful consumer brand in animal health history with FRONTLINE (Flea and tick product for pets) reaching $1billion in annual revenue in 2009.

Before working at Merial, Dr. Jactel was Deputy Minister for Economic and Commercial Affairs at the French Embassy in Washington D.C. Prior to that, he was Assistant Professor at National Veterinary School of Alfort, Paris. He is also a recent founder and board member of Hypercell Technologies LLC, an early-stage biotech company developing therapeutic solutions to serious infectious animal diseases. Dr. Jactel is a Doctor of Veterinary Medicine and has a Masters in Economic Sciences from the Sorbonne University in Paris.

He is a member of the Board of Advisors of the Raleigh Chamber of Commerce and is a Board member of the Veterinary School in Paris.

James Hills

• Non-Executive Director
• Chairman of the Remuneration Committee
• Member of the Nomination and Audit Committees

Mr. Hills was appointed on July 09, 2010. He spent the early portion of his career with The Gillette Company and Coca Cola USA where he held senior positions in both sales and brand management. Later, he became a 50% partner and Chief Executive Officer of Weatherly Consumer Products Inc. (Jobe's), a company which developed, branded and marketed specialty fertilizers in North America and Europe. Following the sale of that business in 1996, he and a partner started Gulfstream Home & Garden, Inc., a company which is specialised in the branding of specialist insecticide products for home and garden use which they sold in 2005, following nearly ten years of rapid growth.

Eric Wintemute

• Non-Executive Director / Chairman & CEO, American Vanguard Corporation
• Member of the Remuneration and Nomination Committees

Eric Wintemute was elected to American Vanguard Corporation's Chairman and Chief Executive Officer posts in mid-1994. Mr. Wintemute had joined the company in January 1994 as Executive Vice President, Chief Operating Officer, and a member of the Board of Directors following American Vanguard's acquisition of GemChem Inc., a national and international chemical distribution company he co-founded in 1991. From 1977 to 1982, he worked for American Vanguard in a variety of sales, purchasing, and production control capacities. Previously, as a Vice President and Director of R.W. Greeff & Co. from 1982 to 1991, Mr. Wintemute oversaw the national and international distribution of key American Vanguard chemical products. Mr. Wintemute holds a Bachelors of Science in Economics from the University of California, San Diego.

Barrington Marshall Riley

• Interim CFO
• Non-Executive Director
• Chairman of the Audit Committee
• Member of the Remuneration and Nomination Committees

Mr Riley was appointed on May 25, 2007. After qualifying as a Chartered Accountant, he joined the Bowater Organization, where he had responsibility for the finance function at several operations. From there he moved to FMC Corporation, the U.S. conglomerate where he had finance and general management responsibilities for a specialty chemical operation, and also oversaw the head office finance function for all UK operations. He joined Proteus International Plc in 1995 as Finance Director and was closely involved in the merger with Therapeutic Antibodies Inc. in 1999, which became Protherics Plc where he was Finance Director until 2007.